| Drug General Information |
| Drug ID |
D0S5RC
|
| Former ID |
DCL000007
|
| Drug Name |
SNS-032
|
| Synonyms |
BMS-387032; BMS-387072; BMS-387032, SNS-032; N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide L-tartaric acid salt (2:1); N-(5-(((5-(1,1-Dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide; N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide; (2R,3R)-2,3-dihydroxybutanedioic acid
|
| Drug Type |
Small molecular drug
|
| Indication |
Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]
|
Phase 1 |
[1],
[2]
|
|---|
| Therapeutic Class |
Anticancer Agents
|
| Company |
Sunesis; Bristol Myers Squibb
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C17H24N4O2S2
|
| InChI |
InChI=1S/C17H24N4O2S2/c1-17(2,3)12-8-19-13(23-12)10-24-14-9-20-16(25-14)21-15(22)11-4-6-18-7-5-11/h8-9,11,18H,4-7,10H2,1-3H3,(H,20,21,22)
|
| InChIKey |
OUSFTKFNBAZUKL-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
8035540, 10043749, 14755895, 36070876, 50069793, 50100091, 50550338, 57352548, 93309880, 99437001, 99451015, 103229612, 103853138, 103905658, 111614343, 124757032, 124772085, 125163836, 125571016, 126577741, 126666806, 126729171, 126735498, 131480704, 135215937, 136340213, 136367332, 136367781, 137276011, 142439008, 143497596, 144233365, 152038136, 152240014, 152258053, 152344090, 160646891, 162011577, 162037466, 162202565, 162840915, 163412142, 164765032, 165237971, 174007077, 174529000, 177748740, 178102298, 180386839, 184819914
|
| Target and Pathway |
| Target(s) |
Cell division protein kinase 9 |
Target Info |
Inhibitor |
[1],
[3]
|
|---|
| Cell division protein kinase 2 |
Target Info |
Inhibitor |
[1],
[3]
|
| Cell division protein kinase 7 |
Target Info |
Inhibitor |
[1],
[3]
|
|
KEGG Pathway
|
Transcriptional misregulation in cancerhsa04068:FoxO signaling pathway
|
|
Cell cycle
|
|
Oocyte meiosis
|
|
p53 signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Hepatitis B
|
|
Measles
|
|
Herpes simplex infection
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
Viral carcinogenesis
|
|
Prostate cancer
|
|
Small cell lung cancerhsa03022:Basal transcription factors
|
|
Nucleotide excision repair
|
|
NetPath Pathway
|
EGFR1 Signaling PathwayNetPath_11:TCR Signaling PathwayNetPath_11:TCR Signaling Pathway
|
|
RANKL Signaling Pathway
|
|
PANTHER Pathway
|
p53 pathway
|
|
p53 pathway feedback loops 2
|
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
|
Signaling events mediated by PRL
|
|
p73 transcription factor network
|
|
E2F transcription factor network
|
|
ATR signaling pathway
|
|
mTOR signaling pathway
|
|
IL2-mediated signaling events
|
|
FoxO family signaling
|
|
FOXM1 transcription factor network
|
|
BARD1 signaling events
|
|
p53 pathway
|
|
Regulation of retinoblastoma proteinretinoic_acid_pathway:Retinoic acid receptors-mediated signaling
|
|
Reactome
|
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcriptionR-HSA-1538133:G0 and Early G1
|
|
Activation of ATR in response to replication stress
|
|
Regulation of APC/C activators between G1/S and early anaphase
|
|
SCF(Skp2)-mediated degradation of p27/p21
|
|
Senescence-Associated Secretory Phenotype (SASP)
|
|
DNA Damage/Telomere Stress Induced Senescence
|
|
Processing of DNA double-strand break ends
|
|
G2 Phase
|
|
Orc1 removal from chromatin
|
|
Cyclin E associated events during G1/S transition
|
|
Cyclin A/B1 associated events during G2/M transition
|
|
p53-Dependent G1 DNA Damage Response
|
|
Cyclin A:Cdk2-associated events at S phase entry
|
|
Meiotic recombination
|
|
Factors involved in megakaryocyte development and platelet productionR-HSA-427413:NoRC negatively regulates rRNA expression
|
|
Formation of TC-NER Pre-Incision Complex
|
|
Dual incision in TC-NER
|
|
Gap-filling DNA repair synthesis and ligation in TC-NER
|
|
Cyclin D associated events in G1
|
|
RNA Polymerase I Transcription Initiation
|
|
WikiPathways
|
Cardiac Hypertrophic Response
|
|
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
|
|
Host Interactions of HIV factors
|
|
HIV Life Cycle
|
|
IL-9 Signaling Pathway
|
|
RNA Polymerase II Transcription
|
|
MicroRNAs in cardiomyocyte hypertrophyWP707:DNA Damage Response
|
|
ID signaling pathway
|
|
DNA Replication
|
|
G1 to S cell cycle control
|
|
M/G1 Transition
|
|
S Phase
|
|
Meiotic Recombination
|
|
Aryl Hydrocarbon Receptor
|
|
ATM Signaling Pathway
|
|
Retinoblastoma (RB) in Cancer
|
|
Spinal Cord Injury
|
|
Integrated Pancreatic Cancer Pathway
|
|
Oncostatin M Signaling Pathway
|
|
Prostate Cancer
|
|
Signaling Pathways in Glioblastoma
|
|
TSH signaling pathway
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Synthesis of DNA
|
|
Regulation of DNA replication
|
|
Mitotic G2-G2/M phases
|
|
Mitotic G1-G1/S phases
|
|
Factors involved in megakaryocyte development and platelet production
|
|
Cell Cycle
|
|
APC/C-mediated degradation of cell cycle proteins
|
|
Cell Cycle Checkpoints
|
|
miRNA Regulation of DNA Damage ResponseWP45:G1 to S cell cycle control
|
|
Eukaryotic Transcription Initiation
|
|
Nucleotide Excision Repair
|
|
RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
|
|
mRNA Capping
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
| References |
| REF 1 | Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45. Epub 2009 Feb 20. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5670). |
|---|
| REF 3 | Development of cell-cycle inhibitors for cancer therapy. Curr Oncol. 2009 Mar;16(2):36-43. |
|---|
